Shareholders meeting

GUJARAT THEMIS BIOSYN LIMITED CIN: L24230GJ1981PLC004878 REGD. OFFICE &FACTORY: 69/C GIDC INDUSTRIAL ESTATE, VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA TEL: 0260-2430027 / 2400639 E-mail:hrm@gtbl.in.net GTBL/BSE/NSE/2026-27/63 21st September 2026 Listing Department Department of Corporate Services National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block-G Phiroze Jeejeebhoy Towers, Dalal Street Bandra Kurla Complex Mumbai 400001 Bandra East, Mumbai 400051 Symbol: GUJTHEM Scrip Code: 506879 Dear Sir / Madam, Subject: Corrigendum to the Notice of Annual General Meeting Gujarat Themis Biosyn Limited (the Company) had sent the notice of 45th Annual General Meeting (“AGM”) of Gujarat Themis Biosyn Limited, which was circulated to the Members on 4th September, 2026, convening the 45th AGM of the Company to be held on Wednesday, 30th September, 2026 at 12:30 p.m. (IST) at 69/A, GIDC Industrial Estate, Vapi-396195, Dist. Valsad, Gujarat The Company, by way this corrigendum, wishes to amend Resolution No. 8 and its explanatory statement to align with applicable provisions of SEBI ICDR Regulations, for consideration and approval of the Members at the ensuing AGM. Consequent to this corrigendum, Resolution No. 8 and explanatory statement related thereto shall be read in conjunction with this corrigendum. All other contents of the Annual General Meeting, save and except as modified or supplemented by the Corrigendum, shall remain unchanged. This is for your information and record please. Thanking you Yours faithfully For Gujarat Themis Biosyn Limited Vineet Gawankar Company Secretary & Compliance Officer MUMBAI OFFICE: Themis House, 11/12 Udyog Nagar, S.V Road, Goregaon (West), Mumbai – 400 104 Tel: 91-22-67607080 / 28757836 Fax: 28746621 / 67607019; E-mail: gtblmumbai@gtbl.in Website Address: www.gtbl.in GUJARAT THEMIS BIOSYN LIMITED CIN: L24230GJ1981PLC004878 REGD. OFFICE & FACTORY: 69/C GIDC INDUSTRIAL ESTATE, VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA https://www.gtbl.in/ TEL: 0260-2430027 / 2400639, E-mail: hrm@gtbl.in.net 1st Corrigendum to AGM Notice Dear Members Gujarat Themis Biosyn Limited (the Company) had sent the notice dated September 2, 2026 (AGM Notice or Notice) for annual general meeting scheduled to be held on Wednesday, September 30, 2026 at 12:30 pm, to the Members of the Company. The Company, through this corrigendum, aims to inform the Members of the Company regarding certain amendments and clarifications (the Amendments) in the Resolution at Item no. 8 of the Notice for raising funds by issue of Equity Shares through Preferential Issue and explanatory statement relating thereto, in compliance with and to align with the applicable laws / SEBI ICDR Regulations. Accordingly, the following Amendments are being made and shall form an integral part of the Notice. 1 In the Notice, page no. 3, in the first para of resolution no. 8, text relating to number of equity shares and amount is substituted by the following texts, due to change is price calculation. “…up to 82,92,081 equity shares of face value of Rs. 1 each of the Company fully paid-up (the Equity Shares), at a price of Rs. 404 per equity share (the Issue Price), aggregating up to Rs. 335,00,00,724/-…” 2 In the Notice, page no. 3, in the first para of resolution no. 8, table containing details relating to the proposed allottees shall be substituted by the following table with updated details of the shares and amounts. There is no change in names of the proposed allottees. No. Name of the Investor or Proposed Allottee No. of Total amount to Category Equity shares be paid, (In Rs) to be allotted 1 Pharmaceutical Business Group (India) Limited 61,88,121 250,00,00,884 Promoter Group 2 Yusuf Khwaja Hamied 2,47,526 10,00,00,504 Public 3 Special Situation India Fund 4,64,108 18,74,99,632 Public 4 India Special Assets Fund III 6,90,594 27,89,99,976 Public 5 ISAF III Onshore Fund 7,01,732 28,34,99,728 Public 3 In the Notice, page no. 14, in Sr. No. 1 (About the Issue), the amount is substituted by the amount as “Rs. 335,00,00,724”. 4 In the Notice, page no. 15, in Sr. No. 2 (Objects of the Issue and timeline), the table below first para is replaced with the following table with intent to make the object clause clearer and precise, without changing the objects. GUJARAT THEMIS BIOSYN LIMITED Sr. Objects for which fund to utilize Amount to be Timelines for No. utilised, Rs. utilization 1 Redemption of Non-convertible debenture (NCDs) and/or 310,00,00,724 12 months Repayment / prepayment of the borrowing and interest thereon availed / to be availed for payment of consideration and cost of acquisition of 100% equity stake in MicroBiopharm Japan Co., Ltd. (including by way of investment in the Company’s subsidiary in Japan in form of capital contribution / loan). 2 General Corporate Purposes (not exceed 25%)* 25,00,00,000 12 months Total 335,00,00,724 The para under the heading “Interim Use of Issue Proceeds” is replaced with the following para with intent to make it precise and in line with appliable guidelines. “Pending complete utilization of the Issue Proceeds for the Objects described above, the Company intends to invest the Issue Proceeds in deposits in scheduled commercial banks, securities issued by government of India and/or creditworthy instruments as permitted under applicable laws / guidelines.” 5 In the Notice, page no. 16, in Sr. No. 3 (Monitoring of utilization of funds), the existing texts is replaced with the following texts with name of the agency. “India Rating and Research Private Limited, a SEBI registered agency, is appointed as the monitoring agency to monitor the utilization of the Issue Proceeds in accordance with the applicable provisions of the SEBI ICDR Regulations.” 6 In the Notice, page no. 16, in Sr. No. 4 (Relevant Date), the following text is inserted at the end of the existing para, “The Relevant Date is August 31, 2026.” 7 In the Notice, page no. 16, in Sr. No. 5 (Basis or justification for the price (including the premium, if any), the 2nd and 3rd para is replaced with the following paras due to change in calculation of floor and issue price, as per pricing formula as per the SEBI ICDR Regulations. “The floor price for the Equity Shares is Rs. 403.82, as per the pricing formula prescribed under the SEBI ICDR Regulations for the Preferential Issue and is the highest of the following. a) 90 trading days volume weighted average price of the equity shares of the Company preceding the Relevant Date, ie Rs. 384.09 per equity share. b) 10 trading days volume weighted average price of the equity shares of the Company preceding the Relevant Date, ie Rs. 403.82 per equity share. The Issue Price cannot be less than the floor price as mentioned above. It has approved the issue price of Rs. 404/- per Equity Share (including premium of Rs. 403 per share), being not less than the floor price computed in accordance with Chapter V / applicable provisions of the SEBI ICDR Regulations.” 8 In the Notice, page no. 16, in Sr. No. 6 (The amount which the Company intends to raise by way of such securities), the amount is substituted by the amount as Rs. 335,00,00,724. 9 In the Notice, page no. 17, in Sr. No. 9 in first para, the amount should be read as Rs. 335,00,00,724, and in the second para the number of shares be read as 82,92,081. GUJARAT THEMIS BIOSYN LIMITED 10 In the Notice, page no. 17, in Sr. No. 10, the first para is replaced with the following texts with name of the promoter group allottee. “Pharmaceutical Business Group (India) Limited, a promoter group entity is intended to subscribe to Equity Shares as mentioned in the resolution and the Statement.” 11 In the Notice, page no. 17, in Sr. No. 11 (Shareholding pattern of the issuer before and after preferential issue), the table is replaced with the following table with updated post shareholding. Sr. Category of Shareholder(s) Pre Issue Post Issue No. No. of % of share No. of % of share shares hel [Showing first 8,000 characters — download PDF for full document]